Huntington Bancshares Incorporated
1.90xPrice / tangible book
Market cap
$34.52B
Tangible equity
$18.20B
Price / tangible book
1.90x
Price / book
1.42x
Return on equity
9.1%
Return on assets
1.0%
Efficiency ratio
40.2%
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HBAN stock price at discount vs BMRN $17.03 current versus $51.38 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at HBAN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple discount
Multiple discount
Profitability edge
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: HBAN FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$34.52B
Tangible equity
$18.20B
Price / tangible book
1.90x
Price / book
1.42x
Return on equity
9.1%
Return on assets
1.0%
Efficiency ratio
40.2%
Price / tangible book
Market cap
$12.88B
Tangible equity
$5.68B
Price / tangible book
2.27x
Price / book
2.12x
Return on equity
5.7%
Return on assets
4.6%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Huntington Bancshares Incorporated · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.76x
0.08x
Net debt / EBITDA
Leverage against operating earnings
—
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
—
$1.31B
Total debt
Interest-bearing obligations outstanding
$18.48B
$505.32M
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
HBAN vs JPM
Bank of America Corporation
HBAN vs BAC
Wells Fargo & Company
HBAN vs WFC
Citigroup Inc.
HBAN vs C
PNC FINANCIAL SERVICES GROUP, INC.
HBAN vs PNC
VERTEX PHARMACEUTICALS INC / MA
HBAN vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
HBAN vs ALNY
Sarepta Therapeutics, Inc.
HBAN vs SRPT
REGENXBIO Inc.
HBAN vs RGNX
IONIS PHARMACEUTICALS INC
HBAN vs IONS
PTC THERAPEUTICS, INC.
HBAN vs PTCT
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.